These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 21789113)

  • 81. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
    Patel DK
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
    [TBL] [Abstract][Full Text] [Related]  

  • 82. ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.
    Segelov E; Waring P; Desai J; Wilson K; Gebski V; Thavaneswaran S; Elez E; Underhill C; Pavlakis N; Chantrill L; Nott L; Jefford M; Khasraw M; Day F; Wasan H; Ciardiello F; Karapetis C; Joubert W; van Hazel G; Haydon A; Price T; Tejpar S; Tebbutt N; Shapiro J
    BMC Cancer; 2016 May; 16():339. PubMed ID: 27246726
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer.
    Satake H; Kagawa Y; Shinozaki E; Tanizawa Y; Jin L; Cai Z; Makiyama A
    Adv Ther; 2022 Jun; 39(6):2596-2613. PubMed ID: 35384550
    [TBL] [Abstract][Full Text] [Related]  

  • 84. First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients.
    Moiseyenko VM; Moiseyenko FV; Yanus GA; Kuligina ES; Sokolenko AP; Bizin IV; Kudriavtsev AA; Aleksakhina SN; Volkov NM; Chubenko VA; Kozyreva KS; Kramchaninov MM; Zhuravlev AS; Shelekhova KV; Pashkov DV; Ivantsov AO; Venina AR; Sokolova TN; Preobrazhenskaya EV; Mitiushkina NV; Togo AV; Iyevleva AG; Imyanitov EN
    Clin Drug Investig; 2018 Jun; 38(6):553-562. PubMed ID: 29470838
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis.
    Parisi A; Ghidini M; Giampieri R; Tomasello G; Luciani A; Ferri C; Berardi R; Petrelli F
    Clin Colorectal Cancer; 2022 Sep; 21(3):e162-e170. PubMed ID: 35184993
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab.
    Williams KJ; Lockhart AC
    Onco Targets Ther; 2009 Feb; 2():161-70. PubMed ID: 20616903
    [TBL] [Abstract][Full Text] [Related]  

  • 87. EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis.
    Jiang Z; Li C; Li F; Wang X
    PLoS One; 2013; 8(2):e56205. PubMed ID: 23441167
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Colorectal Cancer: Disease Process, Current Treatment Options, and Future Perspectives.
    Adebayo AS; Agbaje K; Adesina SK; Olajubutu O
    Pharmaceutics; 2023 Nov; 15(11):. PubMed ID: 38004598
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The role of personalized medicine in metastatic colorectal cancer: an evolving landscape.
    Moorcraft SY; Smyth EC; Cunningham D
    Therap Adv Gastroenterol; 2013 Sep; 6(5):381-95. PubMed ID: 24003339
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Chemotherapy and Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer.
    Tuca A; Gallego R; Ghanem I; Gil-Raga M; Feliu J
    J Clin Med; 2020 Dec; 9(12):. PubMed ID: 33322567
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Predictive and prognostic markers in colorectal cancer.
    Wilson PM; Ladner RD; Lenz HJ
    Gastrointest Cancer Res; 2007 Nov; 1(6):237-46. PubMed ID: 19262902
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Current evidence and controversies in the incorporation of biologics for metastatic colorectal cancer.
    Ciombor KK; Goldberg RM
    Hepat Oncol; 2014 Jun; 1(3):331-345. PubMed ID: 30190967
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Future of targeted agents in metastatic colorectal cancer.
    Burotto M; Hartley ML; Marshall JL; Pishvaian MJ
    Colorectal Cancer; 2012 Oct; 1(5):. PubMed ID: 24273599
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Effectiveness of Standard Treatment for Stage 4 Colorectal Cancer: Traditional Management with Surgery, Radiation, and Chemotherapy.
    Feria A; Times M
    Clin Colon Rectal Surg; 2024 Mar; 37(2):62-65. PubMed ID: 38322607
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The current state of targeted agents in rectal cancer.
    Kim DD; Eng C
    Int J Surg Oncol; 2012; 2012():406830. PubMed ID: 22675625
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Gene signatures derived from transcriptomic-causal networks stratified colorectal cancer patients for effective targeted therapy.
    Yazdani A; Lenz HJ; Pillonetto G; Mendez-Giraldez R; Yazdani A; Sanof H; Hadi R; Samiei E; Venook AP; Ratain MJ; Rashid N; Vincent BG; Qu X; Wen Y; Kosorok M; Symmans WF; Shen JPYC; Lee MS; Kopetz S; Nixon AB; Bertagnolli MM; Perou CM; Innocenti F
    Res Sq; 2023 Dec; ():. PubMed ID: 38168324
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents.
    El Zouhairi M; Charabaty A; Pishvaian MJ
    Gastrointest Cancer Res; 2011 Jan; 4(1):15-21. PubMed ID: 21464866
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Colorectal cancer: Recent advances in management and treatment.
    Fadlallah H; El Masri J; Fakhereddine H; Youssef J; Chemaly C; Doughan S; Abou-Kheir W
    World J Clin Oncol; 2024 Sep; 15(9):1136-1156. PubMed ID: 39351451
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers.
    Yalçin S
    Gastrointest Cancer Res; 2009 Sep; 3(5):197-203. PubMed ID: 20084161
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Colorectal Cancer: An Update on Treatment Options and Future Perspectives.
    Florescu-Ţenea RM; Kamal AM; Mitruţ P; Mitruţ R; Ilie DS; Nicolaescu AC; Mogoantă L
    Curr Health Sci J; 2019; 45(2):134-141. PubMed ID: 31624639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.